Informações:
Falhas:
ID
36573
Descrição
Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01784757
Link
https://clinicaltrials.gov/show/NCT01784757
Palavras-chave
Versões (2)
- 17/01/2019 17/01/2019 -
- 22/05/2019 22/05/2019 -
Titular dos direitos
Orion Corporation, Orion Pharma
Transferido a
22 de maio de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Bioavailability of ODM-201 in Prostate Cancer NCT01784757
Eligibility Criteria
- StudyEvent: Eligibility
Similar models
Eligibility Criteria
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Informed consent
Item
written informed consent (ic) obtained.
boolean
C0021430 (UMLS CUI [1])
histologically confirmed adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of prostate
boolean
C0679557 (UMLS CUI [1,1])
C0007112 (UMLS CUI [1,2])
C0007112 (UMLS CUI [1,2])
progressive metastatic disease
Item
progressive metastatic disease
boolean
C2939420 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0205329 (UMLS CUI [1,2])
ongoing androgen deprivation therapy with LHRH analogue or antagonist or bilateral orchiectomy
Item
ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (LHRH) analogue or antagonist or bilateral orchiectomy
boolean
C0521116 (UMLS CUI [1,1])
C0279492 (UMLS CUI [1,2])
C1518041 (UMLS CUI [1,3])
C0521116 (UMLS CUI [2,1])
C0279492 (UMLS CUI [2,2])
C1276926 (UMLS CUI [2,3])
C0194875 (UMLS CUI [3])
C0279492 (UMLS CUI [1,2])
C1518041 (UMLS CUI [1,3])
C0521116 (UMLS CUI [2,1])
C0279492 (UMLS CUI [2,2])
C1276926 (UMLS CUI [2,3])
C0194875 (UMLS CUI [3])
adequate bone marrow, hepatic and renal function
Item
adequate bone marrow, hepatic and renal function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
able to swallow study treatment as capsule or tablet
Item
able to swallow the ODM-201 whole as a capsule or tablet
boolean
C2712086 (UMLS CUI [1,1])
C0006935 (UMLS CUI [1,2])
C2712086 (UMLS CUI [2,1])
C0039225 (UMLS CUI [2,2])
C0006935 (UMLS CUI [1,2])
C2712086 (UMLS CUI [2,1])
C0039225 (UMLS CUI [2,2])
previous chemotherapy for prostate cancer
Item
previous chemotherapy for prostate cancer
boolean
C1514457 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,2])
known metastases in the brain
Item
known metastases in the brain
boolean
C0220650 (UMLS CUI [1])
history of other malignancy, except a basal cell carcinoma of skin
Item
history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin
boolean
C0262926 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C2828389 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1123023 (UMLS CUI [2,3])
C0205394 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C2828389 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1123023 (UMLS CUI [2,3])
known gastrointestinal condition that can significantly affect the absorption of the study treatment
Item
known gastrointestinal condition that can significantly affect the absorption of the study treatment
boolean
C0017178 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0392760 (UMLS CUI [1,3])
C0237442 (UMLS CUI [1,4])
C0013230 (UMLS CUI [1,5])
C0750502 (UMLS CUI [1,2])
C0392760 (UMLS CUI [1,3])
C0237442 (UMLS CUI [1,4])
C0013230 (UMLS CUI [1,5])